Ensifentrine, a Novel PDE3 and PDE4 Inhibitor for the Treatment of COPD: Randomized, Double-Blind, Placebo-controlled, Multicenter, Phase III Trials (The ENHANCE Trials)

By sjmartinez • June 27, 2023

Anzueto A, Barjaktarevic IZ, Siler TM, Rheault T, Bengtsson T, Rickard K, Sciurba F; ENHANCE investigators. Ensifentrine, a Novel PDE3 and PDE4 Inhibitor for the Treatment of COPD: Randomized, Double-Blind, Placebo-controlled, Multicenter, Phase III Trials (The ENHANCE Trials). Am J Respir Crit Care Med. 2023 Jun 26. doi: 10.1164/rccm.202306-0944OC. Epub ahead of print. PMID: 37364283.

Tags: COPD, ensifentrine, nebulized, PDE3 and PDE4 inhibitor, Publications, Pulmonary, Critical Care & Sleep Medicine

Prediction of Early Neoadjuvant Chemotherapy Response of Breast Cancer through Deep Learning-based Pharmacokinetic Quantification of DCE MRI

Wu C, Wang L, Wang N, Shiao S, Dou T, Hsu YC, Christodoulou AG, Xie Y, Li D. Prediction of Early Neoadjuvant Chemotherapy Response of[...]

Guideline-directed medical therapy and in-hospital mortality in acute coronary syndrome patients with advanced renal dysfunction: analysis of two nationwide retrospective cohort studies

Jin Z, Aa G, Guo Y, Liu H, Sun H, Li Z, Ma M, Fonarow G, Gao Y, Zhao D, Yang Q, Zhou X; CCC-AF[...]

Three-Dimensional Printing of the Human Pericardium to Facilitate Understanding of the Pericardial Reflections, Recesses, and Sinuses

Miyazaki Y, Rimmer M, Peacock WJ, Xu S, Shivkumar K, Mori S. Three-Dimensional Printing of the Human Pericardium to Facilitate Understanding of the Pericardial Reflections,[...]